Penn Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Penn Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-27,077	Closed	-$2.84M	–	158
2022 Q4	$2.84M	Sell	27,077 -951	-3%	-$89.3K	0.29%	89
2022 Q3	$2.41M	Buy	28,028 +23,131	+472%	+$2.06M	0.27%	95
2022 Q2	$406K	Buy	4,897 +906	+23%	+$72.1K	0.04%	170
2022 Q1	$308K	Sell	3,991 -19	-0.5%	-$1.59K	0.03%	187
2021 Q4	$354K	Sell	4,010 -107	-3%	-$8.83K	0.04%	196
2021 Q3	$318K	Sell	4,117 -125	-3%	-$9.86K	0.03%	189
2021 Q2	$354K	Buy	4,242 +721	+20%	+$57.2K	0.03%	200
2021 Q1	$266K	Buy	3,521 +62	+2%	+$5.07K	0.03%	201
2020 Q4	$303K	Buy	+3,459	New	+$274K	0.04%	188

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Penn Capital Management's BMRN Position: Q1 2023 in Review

Penn Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 27,077 shares — an estimated $2.84M sold.

Penn Capital Management first reported a position in BMRN in Q4 2020 and held it in 9 quarters. The position peaked at $2.84M in Q4 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Penn Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Penn Capital Management sold 27,077 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $2.84M.
Penn Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 9 quarters.
Penn Capital Management's BioMarin Pharmaceuticals position peaked at $2.84M in Q4 2022.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Penn Capital Management's 13F filing for Q1 2023, filed 12 May 2023.